JOHNSON & JOHNSON’s PROCRIT (EPOETIN) SALES DOUBLE IN U.S. IN FOURTH QUARTER, FIRM TELLS ANALYSTS; RISPERDAL ANTIPSYCHOTIC NDA AT FDA SINCE APRIL

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".